Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):134-40. Review.

PMID:
15471217
2.

Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.

Baxevanis CN, Papamichail M.

Cancer Immunol Immunother. 2004 Oct;53(10):893-903. Epub 2004 May 26. Review.

PMID:
15168086
3.

Prospects and limitations of T cell receptor gene therapy.

Coccoris M, de Witte MA, Schumacher TN.

Curr Gene Ther. 2005 Dec;5(6):583-93. Review.

PMID:
16457648
4.

Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.

Willemsen R, Chames P, Schooten E, Gratama JW, Debets R.

Cytometry A. 2008 Nov;73(11):1093-9. doi: 10.1002/cyto.a.20644. Review.

5.

Breast cancer immunotherapy.

Zhou J, Zhong Y.

Cell Mol Immunol. 2004 Aug;1(4):247-55. Review.

6.

T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.

Bobisse S, Zanovello P, Rosato A.

Expert Opin Biol Ther. 2007 Jun;7(6):893-906. Review.

PMID:
17555374
7.
8.
9.

The T-body approach: redirecting T cells with antibody specificity.

Eshhar Z.

Handb Exp Pharmacol. 2008;(181):329-42. Review.

PMID:
18071952
10.

Is antigen specificity the key to efficient adoptive T-cell therapy?

Labarriere N, Khammari A, Lang F, Dreno B.

Immunotherapy. 2011 Apr;3(4):495-505. doi: 10.2217/imt.11.16. Review.

PMID:
21463191
11.

Preclinical development of T cell receptor gene therapy.

Bendle GM, Haanen JB, Schumacher TN.

Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Epub 2009 Mar 25. Review.

PMID:
19321326
12.

Exploiting T cell receptor genes for cancer immunotherapy.

Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ.

Clin Exp Immunol. 2005 Feb;139(2):167-72. Review.

13.

Antigenic targets for renal cell carcinoma immunotherapy.

Vieweg J, Jackson A.

Expert Opin Biol Ther. 2004 Nov;4(11):1791-801. Review.

PMID:
15500407
14.

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Jotereau F, Gervois N, Labarrière N.

Target Oncol. 2012 Mar;7(1):3-14. doi: 10.1007/s11523-012-0207-z. Epub 2012 Feb 15. Review.

PMID:
22350487
15.

Adoptive T-cell therapy of cancer.

Erbayraktar Z.

J BUON. 2009 Sep;14 Suppl 1:S193-201. Review.

PMID:
19785066
16.

Prospects and limitations of T cell receptor gene therapy.

Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN.

Curr Gene Ther. 2011 Aug;11(4):276-87. Review.

PMID:
21453279
17.

Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.

Liu L, Sun M, Wang Z.

Cancer Lett. 2012 Mar;316(1):1-5. doi: 10.1016/j.canlet.2011.10.027. Epub 2011 Oct 29. Review.

PMID:
22099879
18.

Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.

Kershaw MH, Trapani JA, Smyth MJ.

Ther Immunol. 1995 Jun;2(3):173-81. Review.

PMID:
8885135
19.

Suicide genes as safety switches in T lymphocytes.

Straathof KC, Spencer DM, Sutton RE, Rooney CM.

Cytotherapy. 2003;5(3):227-30. Review.

PMID:
12850790
20.

Development and application of receptor-modified T lymphocytes for adoptive immunotherapy.

Geiger TL, Jyothi MD.

Transfus Med Rev. 2001 Jan;15(1):21-34. Review. No abstract available.

PMID:
11149976

Supplemental Content

Support Center